{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:01:28Z","timestamp":1789142488771,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bioorg.2020.104198","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T21:47:01Z","timestamp":1598564821000},"page":"104198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors"],"prefix":"10.1016","volume":"104","author":[{"given":"Essam","family":"Eldin A. Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura S.","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham F.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"El-Moghazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bioorg.2020.104198_b0005","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Ame","year":"2004","journal-title":"BioEssays"},{"issue":"167","key":"10.1016\/j.bioorg.2020.104198_b0010","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000902","article-title":"Poly (ADP-ribose)(PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1\u2013dependent cell death (parthanatos)","volume":"4","author":"Wang","year":"2011","journal-title":"Sci. Signal"},{"issue":"1","key":"10.1016\/j.bioorg.2020.104198_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"issue":"12","key":"10.1016\/j.bioorg.2020.104198_b0020","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/jm100012m","article-title":"Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic","volume":"53","author":"Ferraris","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7381","key":"10.1016\/j.bioorg.2020.104198_b0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"5747","key":"10.1016\/j.bioorg.2020.104198_b0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/283593a0","article-title":"(ADP-ribose)n participates in DNA excision repair","volume":"283","author":"Durkacz","year":"1980","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bioorg.2020.104198_b0035","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1535-7163.MCT-09-1027","article-title":"Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair","volume":"9","author":"Loser","year":"2010","journal-title":"Mol. Can. Ther."},{"key":"10.1016\/j.bioorg.2020.104198_b0040","doi-asserted-by":"crossref","unstructured":"M.E. Moynahan, M.J.N.r.M.c.b. Jasin, Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis, Nat Rev Mol Cell Biol, 11(3) (2010) 196\u2013207.","DOI":"10.1038\/nrm2851"},{"key":"10.1016\/j.bioorg.2020.104198_b0045","doi-asserted-by":"crossref","unstructured":"M.R.J.N.s. Lieber, m. biology, NHEJ and its backup pathways in chromosomal translocations, Nat Struct Mol Biol, 17(4) (2010) 393\u2013395.","DOI":"10.1038\/nsmb0410-393"},{"issue":"11","key":"10.1016\/j.bioorg.2020.104198_b0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","article-title":"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage","volume":"95","author":"Yoshida","year":"2004","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.bioorg.2020.104198_b0055","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nsmb.2096","article-title":"Unraveling the mechanism of BRCA2 in homologous recombination","volume":"18","author":"Holloman","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7035","key":"10.1016\/j.bioorg.2020.104198_b0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.bioorg.2020.104198_b0065","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bioorg.2020.104198_b0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104198_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.maturitas.2009.06.010","article-title":"Triple-negative breast cancer: novel therapies and new directions","volume":"63","author":"Pal","year":"2009","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.bioorg.2020.104198_b0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40265-016-0688-7","article-title":"PARP inhibitors in reproductive system cancers: current use and developments","volume":"77","author":"O'Sullivan Coyne","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bioorg.2020.104198_b0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/13543776.2017.1259413","article-title":"PARP inhibitors as antitumor agents: a patent update (2013\u20132015)","volume":"27","author":"Yuan","year":"2017","journal-title":"Expert. Opin. Ther. Pat."},{"issue":"21","key":"10.1016\/j.bioorg.2020.104198_b0090","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2020.104198_b0095","first-page":"229","article-title":"PARP inhibitors plough on","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2020.104198_b0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cell.2017.03.034","article-title":"PARP inhibitors for cancer therapy","volume":"169","author":"Lin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2020.104198_b0105","doi-asserted-by":"crossref","unstructured":"FDA approves PARP inhibitor for ovarian cancer, Nat. Biotechnol. 35(5) (2017) 398.","DOI":"10.1038\/nbt0517-398"},{"key":"10.1016\/j.bioorg.2020.104198_b0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejmech.2017.03.013","article-title":"Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity","volume":"132","author":"Zhou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2020.104198_b0115","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.bmcl.2017.04.038","article-title":"Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach","volume":"27","author":"Chadha","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104198_b0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ejmech.2018.01.018","article-title":"Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors","volume":"145","author":"Chen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104198_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103181","article-title":"Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors","volume":"91","author":"Zhong","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2020.104198_b0130","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1039\/C8OB00286J","article-title":"Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1\/2 inhibitors: design, synthesis and their antitumor activity","volume":"16","author":"Zhou","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2020.104198_b0135","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bioorg.2019.03.068","article-title":"Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold","volume":"87","author":"Elmasry","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2020.104198_b0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1134\/S0006297918020074","article-title":"2,5-Diketopiperazines: A new class of poly(ADP-ribose)polymerase inhibitors","volume":"83","author":"Nilov","year":"2018","journal-title":"Biochemistry (Mosc)"},{"issue":"6","key":"10.1016\/j.bioorg.2020.104198_b0145","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/mol.108.048751","article-title":"Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors","volume":"74","author":"Eltze","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioorg.2020.104198_b0150","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2020.104198_b0155","doi-asserted-by":"crossref","unstructured":"M.J.T.J.o.P.C. Krahl, The effect of variation in ionic strength and temperature on the apparent dissociation Cconstants of thirty substituted barbituric acids, J Phys Chem, 44(4) (1940), pp. 449-463.","DOI":"10.1021\/j150400a010"},{"key":"10.1016\/j.bioorg.2020.104198_b0160","doi-asserted-by":"crossref","unstructured":"U. Schatzschneider, T. Weyherm\u00fcller, E.J.E.J.o.I.C. Rentschler, Metal Complexes with Nitronyl Nitroxide Substituted Phenolate Ligands Providing New Magnetic Exchange Interaction Pathways\u2212 Synthesis, Structures, Magnetic Dilution Studies, and Ab Initio Calculations, Eur. J. Inorg. Chem., 2001(10) (2001), pp. 2569-2586.","DOI":"10.1002\/1099-0682(200109)2001:10<2569::AID-EJIC2569>3.0.CO;2-3"},{"key":"10.1016\/j.bioorg.2020.104198_b0165","doi-asserted-by":"crossref","unstructured":"J. Dickey, A. Gray, Barbituric acid, Organic Syntheses, 18 (2003), pp. 8-8.","DOI":"10.1002\/0471264180.os018.04"},{"issue":"13","key":"10.1016\/j.bioorg.2020.104198_b0170","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/jm5002502","article-title":"Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors","volume":"57","author":"Patel","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2020.104198_b0175","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol. Can. Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2020.104198_b0180","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","article-title":"BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation","volume":"7","author":"Stordal","year":"2013","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104198_b0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/0008-5472.CAN-05-2853","article-title":"BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants","volume":"66","author":"Elstrodt","year":"2006","journal-title":"Can. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2020.104198_b0190","first-page":"142","article-title":"PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells","volume":"26","author":"Shi","year":"2014","journal-title":"Chin. J. Can. Res."},{"issue":"5","key":"10.1016\/j.bioorg.2020.104198_b0195","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3324\/haematol.2008.001933","article-title":"Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes","volume":"94","author":"Gaymes","year":"2009","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.bioorg.2020.104198_b0200","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1038\/s41388-020-1191-x","article-title":"Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bioorg.2020.104198_b0205","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10549-012-2106-5","article-title":"Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells","volume":"134","author":"Chuang","year":"2012","journal-title":"Breast Can. Res Treat."},{"issue":"6","key":"10.1016\/j.bioorg.2020.104198_b0210","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4161\/cbt.24349","article-title":"Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines","volume":"14","author":"Pierce","year":"2013","journal-title":"Can. Biol. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2020.104198_b0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13046-019-1204-1","article-title":"Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase","volume":"38","author":"Campillo-Marcos","year":"2019","journal-title":"J. Exp. Clin. Can. Res."},{"key":"10.1016\/j.bioorg.2020.104198_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103575","article-title":"Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors","volume":"96","author":"Li","year":"2020","journal-title":"Bioorg Chem"},{"issue":"10","key":"10.1016\/j.bioorg.2020.104198_b0225","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2011","journal-title":"Mol. Can. Ther."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820314954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820314954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:26:52Z","timestamp":1763566012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820314954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"alternative-id":["S0045206820314954"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104198","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104198"}}